{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:18:34Z","timestamp":1783520314882,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02365-5","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:36:25Z","timestamp":1774402585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Kadijah","family":"Porter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Acquah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shea E.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2365_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1001\/jama.297.18.2018","volume":"297","author":"CL Campbell","year":"2007","unstructured":"Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018\u201324. https:\/\/doi.org\/10.1001\/jama.297.18.2018.","journal-title":"JAMA"},{"key":"2365_CR2","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","volume":"316","author":"C Baigent","year":"1998","unstructured":"Baigent C, Collins R, Appleby P, Parish S, Sleight P, Petro R. ISIS-2: 10-year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both or neither. BMJ. 1998;316:1337\u201343. https:\/\/doi.org\/10.1136\/bmj.316.7141.1337.","journal-title":"BMJ"},{"key":"2365_CR3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1161\/CIRCULATIONAHA.116.023952","volume":"134","author":"G Gargiulo","year":"2016","unstructured":"Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A critical appraisal of aspirin in secondary prevention: is less more? Circulation. 2016;134:1881\u2013906. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.023952.","journal-title":"Circulation"},{"key":"2365_CR4","first-page":"349","volume":"ii","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","unstructured":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;ii:349\u201360.","journal-title":"Lancet"},{"key":"2365_CR5","first-page":"221","volume":"11","author":"MR Buchannan","year":"1995","unstructured":"Buchannan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995;11:221\u20137.","journal-title":"Can J Cardiol"},{"key":"2365_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","volume":"336","author":"G Krasopoulos","year":"2008","unstructured":"Krasopoulos G, Brister SJ, Beattie WS, Elliot RF, Buchanan MR. Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195\u20138. https:\/\/doi.org\/10.1136\/bmj.39430.529549.BE.","journal-title":"BMJ"},{"issue":"21","key":"2365_CR7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","volume":"384","author":"WS Jones","year":"2021","unstructured":"Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Mu\u00f1oz D, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. New Engl J Med. 2021;384(21):1981\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2102137.","journal-title":"New Engl J Med"},{"key":"2365_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jamacardio.2016.1017","volume":"1","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Ophuis TO, Steg G, Storey R, Cohen M, et al. Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol. 2016;1:425\u201332. https:\/\/doi.org\/10.1001\/jamacardio.2016.1017.","journal-title":"JAMA Cardiol"},{"key":"2365_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ. 2002;324:71\u201386. https:\/\/doi.org\/10.1136\/bmj.324.7329.71.","journal-title":"BMJ"},{"key":"2365_CR10","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482.","journal-title":"N Engl J Med"},{"key":"2365_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jacc.2013.09.023","volume":"63","author":"P Kohli","year":"2014","unstructured":"Kohli P, Udell JA, Murphy SA, Cannon CP, Antman EA, Braunwalkd E, et al. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel. J Am Coll Cardiol. 2014;63:225\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.023.","journal-title":"J Am Coll Cardiol"},{"key":"2365_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et al. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. N Engl J Med. 2012;366:20\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1109719.","journal-title":"N Engl J Med"},{"key":"2365_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.amjcard.2013.11.052","volume":"113","author":"KW Mahaffey","year":"2014","unstructured":"Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, et al. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST segment elevation acute coronary syndrome (from the TRACER trial). Am J Cardiol. 2014;113:936\u201344. https:\/\/doi.org\/10.1016\/j.amjcard.2013.11.052.","journal-title":"Am J Cardiol"},{"key":"2365_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJMoa0909475","volume":"363","author":"CURRENT-OASIS 7 Investigators","year":"2010","unstructured":"CURRENT-OASIS 7 Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930\u201342. https:\/\/doi.org\/10.1056\/NEJMoa0909475.","journal-title":"N Engl J Med"},{"key":"2365_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators","year":"2001","unstructured":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa010746.","journal-title":"N Engl J Med"},{"key":"2365_CR16","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1161\/01.CIR.0000091201.39590.CB","volume":"108","author":"RJG Peters","year":"2003","unstructured":"Peters RJG, Mehta SR, Fox KAA, Zhao F, Lewis BS, Kopecky SL, et al. Effect of Aspirin Dose When Used Alone or in Combination with Clopidogrel in Patients with Acute Coronary Syndromes. Circulation. 2003;108:1682\u20137. https:\/\/doi.org\/10.1161\/01.CIR.0000091201.39590.CB.","journal-title":"Circulation"},{"key":"2365_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1161\/CIRCULATIONAHA.114.014992","volume":"132","author":"Y Xian","year":"2015","unstructured":"Xian Y, Wang TY, McCoy LA, Effron MB, Henry TD, Bach RG, et al. Association of Discharge Aspirin Dose with Outcomes after Acute Myocardial Infarction. Circulation. 2015;132:174\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014992.","journal-title":"Circulation"},{"key":"2365_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/0049-3848(91)90085-b","volume":"63","author":"KH Grotemeyer","year":"1991","unstructured":"Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients: evidence of nonresponders in a subpopulation of treated patients. Thromb Res. 1991;63:587\u201393. https:\/\/doi.org\/10.1016\/0049-3848(91)90085-b.","journal-title":"Thromb Res"},{"key":"2365_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-j","volume":"71","author":"KH Grotemeyer","year":"1993","unstructured":"Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71:397\u2013403. https:\/\/doi.org\/10.1016\/0049-3848(93)90164-j.","journal-title":"Thromb Res"},{"key":"2365_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/jcm9010194","volume":"9","author":"P Fontana","year":"2020","unstructured":"Fontana P, Roffi M, Reny JL. Platelet function test use for patients with coronary artery disease in the early 2020ss. J Clin Med. 2020;9:194\u2013209. https:\/\/doi.org\/10.3390\/jcm9010194.","journal-title":"J Clin Med"},{"key":"2365_CR21","first-page":"221","volume":"11","author":"MR Buchannan","year":"1995","unstructured":"Buchannan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995;11:221\u20137.","journal-title":"Can J Cardiol"},{"key":"2365_CR22","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1053\/euhj.2000.2515","volume":"22","author":"S Kamath","year":"2001","unstructured":"Kamath S, Blann AD, Lip GYH. Platelet activation: assessment and quantification. Eur Heart J. 2001;22:1561\u201371. https:\/\/doi.org\/10.1053\/euhj.2000.2515.","journal-title":"Eur Heart J"},{"key":"2365_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1172\/JCI108132","volume":"56","author":"GJ Roth","year":"1975","unstructured":"Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624\u201332. https:\/\/doi.org\/10.1172\/JCI108132.","journal-title":"J Clin Invest"},{"key":"2365_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00005344-198007000-00006","volume":"2","author":"EF Ellis","year":"1980","unstructured":"Ellis EF, Wright KF, Jones PS, Richardson DW, Ellis CK. Effect of oral aspirin dose on platelet aggregation and vascular prostacycline (PGI2) synthesis in humans and rats. J Cardiovasc Pharm. 1980;2:387\u201397. https:\/\/doi.org\/10.1097\/00005344-198007000-00006.","journal-title":"J Cardiovasc Pharm"},{"key":"2365_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.7326\/0003-4819-142-5-200503010-00012","volume":"142","author":"S Sanderson","year":"2005","unstructured":"Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142:370\u201380. https:\/\/doi.org\/10.7326\/0003-4819-142-5-200503010-00012.","journal-title":"Ann Intern Med"},{"key":"2365_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/j.1538-7836.2008.02897.x","volume":"6","author":"JL Reny","year":"2008","unstructured":"Reny JL, Moerloose PD, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:444\u201350. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.02897.x.","journal-title":"J Thromb Haemost"},{"key":"2365_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/11318440-000000000-00000","volume":"10","author":"J Herlitz","year":"2010","unstructured":"Herlitz J, T\u00f3th P, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10:125\u201341. https:\/\/doi.org\/10.2165\/11318440-000000000-00000.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2365_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.jacc.2005.05.084","volume":"8","author":"KP Alexander","year":"2005","unstructured":"Alexander KP, Roe MT, Chen AY, Lytle BL, Pollack CV, Foody JM. Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE national quality improvement initiative. JACC. 2005;8:1479\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.084.","journal-title":"JACC"},{"key":"2365_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","volume":"128","author":"MT Roe","year":"2013","unstructured":"Roe MT, Goodman SG, Ohman M, Stevens SR, Hochman JS, Gottlieb S, et al. Elderly Patients with Acute Coronary Syndromes Managed without Revascularization. Circulation. 2013;128:823\u201333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002303.","journal-title":"Circulation"},{"key":"2365_CR30","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa F, van Klaveren D, Heg JS, Raber L, Feres F, Pilgrim T, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025\u20132034. https:\/\/doi.org\/10.1016\/S0140-6736(17)30397-5.","journal-title":"Lancet"},{"key":"2365_CR31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/gutjnl-2020-321585","volume":"70","author":"SE Mahady","year":"2021","unstructured":"Mahady SE, Margolis KL, Chan A, Polekhina G, Woods RL, Wolfe R, et al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut. 2021;70:717\u201324. https:\/\/doi.org\/10.1136\/gutjnl-2020-321585.","journal-title":"Gut"},{"key":"2365_CR32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.amjcard.2013.03.022","volume":"112","author":"M Vaturi","year":"2013","unstructured":"Vaturi M, Vaduganathan M, Bental T, Solodky A, Kornowski R, Lev EI. Relation of aspirin response to age in patients with stable coronary artery disease. Am J Cardiol. 2013;112:212\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2013.03.022.","journal-title":"Am J Cardiol"},{"key":"2365_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026921","volume":"13","author":"G Marquis-Gravel","year":"2024","unstructured":"Marquis-Gravel G, Stebbins A, Wruck LM, Roe MT, Effron MB, Hammill BG, et al. Age and aspirin dosing in secondary prevention of atherosclerotic cardiovascular disease. J Am Heart Assoc. 2024;13:e026921. https:\/\/doi.org\/10.1161\/JAHA.122.026921.","journal-title":"J Am Heart Assoc"},{"key":"2365_CR34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2020.7848","volume":"324","author":"AR Orkaby","year":"2020","unstructured":"Orkaby AR, Driver JA, Ho Y-L, Lu B, Costa L, Honerlaw J, et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. JAMA. 2020;324:68\u201378. https:\/\/doi.org\/10.1001\/jama.2020.7848.","journal-title":"JAMA"},{"key":"2365_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-024-01466-0","volume":"64","author":"NN Ngcobo","year":"2025","unstructured":"Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet. 2025;64:335\u201367. https:\/\/doi.org\/10.1007\/s40262-024-01466-0.","journal-title":"Clin Pharmacokinet"},{"key":"2365_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25803","volume":"6","author":"GC Cloud","year":"2023","unstructured":"Cloud GC, Williamson JD, Thao LTP, Tran C, Eaton CB, Wolfe R, et al. Low-dose aspirin and the risk of stroke and intracerebral bleeding in healthy older people: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6:e2325803. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.25803.","journal-title":"JAMA Netw Open"},{"key":"2365_CR37","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby K, Arnold SA, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients with Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9\u2013119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","journal-title":"Circulation"},{"key":"2365_CR38","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1161\/CIR.0000000000001309","volume":"151","author":"SV Rao","year":"2025","unstructured":"Rao SV, O\u2019Donoghue ML, Ruel M, Rab T, Tamis-Holland JE, Alexander J, et al. 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e771\u2013862. https:\/\/doi.org\/10.1161\/CIR.0000000000001309.","journal-title":"Circulation"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02365-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:36:26Z","timestamp":1774402586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02365-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2365"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02365-5","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"41"}}